New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareChonluten vs DSIP

Chonluten vs DSIP

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Chonluten
Sleep OptimizationCognitive Enhancement
DSIP
Summary
Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
DSIP is an endogenous neuropeptide originally isolated from rabbit cerebrospinal fluid that induces delta-wave (deep) sleep. It also modulates stress response, cortisol regulation, and LH secretion, making it valuable for sleep optimization and stress management.
Half-Life
Short (minutes for the peptide); sustained gene-regulatory effects
~30–60 minutes; however downstream sleep effects last 4–6 hours
Admin Route
SubQ, Oral
SubQ, IV, Intranasal
Research
Typical Dose
10 mg per day
100–400 mcg
Frequency
Daily for 10–30 days
Once nightly
Key Benefits
  • Supports bronchial mucosal regeneration and repair
  • May improve mucociliary clearance in chronic respiratory conditions
  • Anti-inflammatory effects on bronchial epithelium
  • Pulmonary anti-aging and tissue preservation
  • Supports lung function in COPD and chronic bronchitis
  • Well tolerated in combination with other Khavinson bioregulators
  • Short tripeptide with efficient cellular penetration
  • Induces and deepens delta-wave (slow-wave) sleep
  • Reduces cortisol and normalizes HPA axis
  • Improves sleep quality in insomnia patients
  • Anti-stress and anxiolytic effects
  • May improve opiate/alcohol withdrawal symptoms
  • Analgesic properties through opioid modulation
  • Antioxidant and neuroprotective effects
Side Effects
  • Generally well tolerated
  • Mild injection site reactions possible
  • No significant adverse pulmonary events reported
  • Generally well tolerated
  • Mild grogginess next morning at higher doses
  • Rare: hypotension
  • Potential for altered dream patterns
Stacks With